News

Japan plans improved monitoring of new drugs

BMJ 2000; 320 doi: https://doi.org/10.1136/bmj.320.7249.1560/a (Published 10 June 2000) Cite this as: BMJ 2000;320:1560
  1. Joe Lamar
  1. Tokyo

    The Japanese health ministry will ask pharmaceutical companies to monitor the side effects of new drugs under plans it has submitted to politicians and industry leaders. Under the ministry's plan, companies would be obliged to collect data on adverse reactions to new products for a six month period after they come on to the market.

    Although the ministry's drug safety division would continue to play a monitoring role, the onus of information collection and disclosure would be shifted onto corporations.

    In recent years, the Japanese public has been shocked at the slow release of information aboutpotentially dangerous …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe